BeOne Medicines revenue jumps 30% to $1.7 billion
Share
- BeOne Medicines’ second-quarter revenue increased 30% to $1.705 billion, while GAAP net income reached $237 million.
- BRUKINSA revenue rose 31% to $1.2 billion, including $893 million generated in the United States.
- BeOne raised its 2026 revenue guidance to $6.6–$6.8 billion and increased its operating-income forecasts.
BeOne Medicines (NASDAQ:ONC) reported second-quarter revenue of $1.705 billion, up 30%, as BRUKINSA sales expanded globally.
Revenue rose from $1.315 billion a year earlier, while BRUKINSA revenue increased 31% to $1.2 billion, including $893 million in U.S. sales.
GAAP operating income reached $325 million, net income was $237 million, and free cash flow nearly doubled to $435 million.
BeOne raised 2026 revenue guidance to $6.6–$6.8 billion.
BRUKINSA generated $1.2 billion, TEVIMBRA produced $229 million, and Amgen in-licensed products contributed $157 million during the quarter.
BeOne recently expanded its New Jersey manufacturing site, secured U.S. approval for BEQALZI and advanced several late-stage oncology studies.
Frequently asked questions
More from United States
Merck raises FY profit outlook as Q3 revenue climbs 5% to $18.1B
Eli Lilly Q3 revenue surges 39% to $24.4 billion as guidance rises
Enterprise Products Q3 EBITDA jumps 16% to $2.8 billion
KBR Q3 revenue rises 5% to $2 billion as adjusted EBITDA grows 12%
Enerflex Q3 free cash flow rises to $102 million as net earnings climb
WTW Q3 revenue rises 8% to $2.46 billion as AI savings plan advances
